Form: 8-K

Current report filing

November 25, 2014

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 19, 2014

Date of Report (Date of earliest event reported)

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Boulevard

San Diego, California 92123

(Address of Principal Executive Offices) (Zip Code)

(858) 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On November 19, 2014, US Pacific time, at our annual meeting of stockholders, our stockholders (1) elected the three nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2015; and (3) approved the compensation of our named executive officers.

 

     For      Against      Abstain      Broker
Non-Votes		  

Item of Business No. 1: Election of the following three nominees to serve for three-year terms until our annual meeting of stockholders in 2017:

            

Michael Farrell

      99,053,094         77,069         177,480         7,608,684  

Chris Roberts

      95,376,702         3,751,692         179,249         7,608,684  

Jack Wareham

      98,889,484         240,442         177,717         7,608,684   

 

     For      Against      Abstain      Broker
Non-Votes		  

Item No. 2: Ratification of Auditors

      106,258,434         406,582         251,311                              

 

     For      Against      Abstain      Broker
Non-Votes		  

Item No. 3: Approval, on an advisory basis, of the compensation of ResMed’s named executive officers.

      92,577,258         6,339,158         391,227         7,608,684   

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

    RESMED INC.
Date: November 25, 2014     By:  

/s/ David Pendarvis
      Name:   David Pendarvis
      Its:   Chief administrative officer, global general counsel and secretary